The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a ...

Fintel reports that on October 21, 2025, Stifel reiterated coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.

We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ ...

Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. This analytical report serves as a pivotal resource for detailed insights into Dexcom's expansive pipeline, ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...

A multinational analysis and Swedish registry data show higher dementia mortality after age 80 and a twofold dementia risk in ...

The Flinn Foundation recently released the latest version of its Bioscience Roadmap for Arizona — a guide to the sector in ...

McMillan on Thursday provided an update on his newly injured players with Brian Gleeson set for up to 10 weeks on the sidelines.

As a performance-based coach, Lancaster sees “the trajectories going in the right direction” as Connacht now head to Thomond ...